Background: Data are limited regarding adherence to dipeptidyl peptidase-4 inhibitors. Methods: The present retrospective cohort study of a claims database involved adults with type 2 diabetes mellitus, continuous enrollment for 12 months before the first prescription of add-on sitagliptin (SITA) or a sulfonylurea (SU) to metformin (MET) monotherapy (index date), and ≥45 days of MET coverage ≤90 days before the index date. The SITA and SU users were matched on duration of follow-up and propensity score (PS). Logistic regression analysis incorporated age, gender, comorbidities, and concomitant medications as independent variables. Results: Approximately 99 % of SITA patients were PS matched, resulting in 14 807 well-balanced PS-matched SITA/SU pairs. Mean proportion of days covered (PDC) was significantly higher for SITA (vs SU) + MET after 1 year (P < 0.001). Adherence (PDC ≥80 %) to SITA (vs SU) + MET was 59.1 % (vs 55.9 %; P < 0.001) at 1 year and 52.6 % (vs 49.9 %; P = 0.007) at 2 years. Using logistic regression models including out-of-pocket expense (OPE) as a covariate, we found improved mean PDC and adherence for SITA (vs SU) + MET. Numbers of patients who continued to use SITA (vs SU) + MET were significantly higher after Years 1, 2, and 3 (all P < 0.05). Conclusions: Users of SITA + MET had significantly higher mean PDC, adherence, and persistence than those on SU + MET. These trends were robust to model alterations and were more marked when accommodating OPEs.
Introduction
Diabetes is the seventh-leading cause of death in the US (as of 2007), causes suffering for millions, and hence constitutes a major burden to the US healthcare system. Of all American adults aged ≥20 years, 11.3 % (25.6 million) have diabetes. 1 Approximately 90 % of patients with diabetes have type 2 diabetes mellitus (T2DM), approximately 58 % of these individuals are treated with oral antihyperglycemic agents (OAHAs), and a further 14 % receive both OAHAs and insulin. 1 Glucose control can be enhanced, and diabetic morbidity, mortality, and long-term health resource utilization (including costs) reduced, via improved adherence to these medications. [2] [3] [4] [5] [6] [7] [8] [9] [10] Adherence is commonly defined as the extent of agreement between provider guidance and patient behaviors. Reduced healthcare utilization with enhanced antidiabetic medication adherence more than offsets increased short-term medication costs and includes lower frequencies of visits to emergency departments and hospital admissions. 5 Despite these potential benefits, adherence to OAHAs is as low as 31 %-67 % (depending largely on definitions). [11] [12] [13] [14] [15] [16] [17] In a review of 38 studies on diabetes management, the 12-month OAHA persistence (adherence over time) was only 62 %. 15 A European survey of patients with T2DM revealed that only 39 % of respondents self-reported good adherence. 16 To keep pace with the progressive nature of T2DM, patient-centered stepwise pharmacotherapy is often required. 18, 19 If lifestyle modification and/or treatment with the biguanide metformin (MET) do not adequately control glucose, consensus statements recommend that other OAHAs be added. 18, 20 These second-line OAHAs include sulfonylureas (SUs) and dipeptidyl peptidase (DPP)-4 inhibitors. The DPP-4 inhibitors and MET have potentially complementary mechanisms of action, in that MET can increase the release of glucagon-like peptide (GLP-1), whereas DPP-4 inhibitors reduce its enzymatic degradation. [21] [22] [23] Unlike the case with SUs, doses of DPP-4 inhibitors do not need to be uptitrated. 24 These medications and other incretin mimetics have glucosedependent effects on both pancreatic α-and β-cell secretory activities. 25 Conversely, SUs stimulate β-cell secretory activity in a glucose-independent manner. 26 Largely because of these distinctions, combination therapy with DPP-4 inhibitors + MET may result in lower risks of two major barriers to OAHA adherence (weight gain and hypoglycemia) compared with SUs + MET. 27, 28 A systematic review of randomized controlled trials showed that SUs were associated with a mean weight gain of 2.06 kg (4.53 lb) compared with placebo, whereas DPP-4 inhibitors were weight neutral or slightly weight reducing. 27 Moreover, SU treatment was associated with a greater than fourfold increased likelihood of hypoglycemia (relative risk [RR] 4.57 vs placebo), whereas the frequency of hypoglycemia with DPP-4 inhibitors did not differ from placebo (RR 0.63; 95 % confidence interval [CI] 0.26-1.71). 27 Data are needed to inform clinical decisions about second-line OAHAs as adjuncts to MET, including adherence with these combination regimens. Patients with T2DM may over-report, and some clinicians may overestimate, medication adherence levels. 29 Randomized controlled trials that monitor highly "selected" patient populations very closely may also report greater adherence than what would be observed in a real-world setting. However, observational cohort studies, conducted in naturalistic clinical settings, enable large numbers of patients with T2DM to be followed in situ for prolonged intervals, increasing the generalizability of findings to typical-care practices.
Health economics studies have demonstrated that affordability is an important determinant of adherence to medications for chronic diseases. In particular, a number of studies of patients with diabetes (and certain other chronic conditions, such as hypertension) have demonstrated that increasing patient costs (i.e. out-of-pocket expenses) are associated with reduced adherence to OAHAs and other diabetes therapies. 13, 30, 31 Conversely, "gap coverage" in (US) Medicare and other means of increasing insurance coverage to help shoulder a patient's economic burden promote higher adherence to OAHAs. 32, 33 To evaluate "real-world" patient uses of adjunctive MET regimens, the present study sought to evaluate medication adherence, persistence with medication, and time to treatment discontinuation among patients initiating either SITA or SUs as add-ons to ongoing MET treatment. Statistical models were used to help assess the effects of out-of-pocket expenses on associations between the use of SITA (vs SUs) + MET and medication adherence.
Methods
The present retrospective cohort study analyzed a US administrative-claims database (MarketScan® Commercial Claims and Encounters and Medicare Supplemental Databases; Truven Health Analytics, Ann Arbor, MI, USA). This database contains electronic health claims data from >150 million unique privately insured patients since 1996, and 40 million patients each year, from a geographically diverse population in all 50 states. Together, these large insurance claims databases from >100 employers are representative of the national commercially insured population in the US, as well as individuals who have both Medicare and supplemental coverage. Information is captured across multiple healthcare settings, including physician office visits, hospital stays, and outpatient pharmacy claims. The MarketScan database is Health Insurance Portability and Accountability Act (HIPAA) compliant. Deidentified patient data related to medication adherence, persistence, and time to discontinuation in different cohorts were collected. Figure 1 shows the study design and timeline. The study extended from 1 January 2008 through 31 March 2013 (study period). At baseline, eligible patients were receiving only MET. The index date was defined by the first SU or SITA pharmacy claim (service date), or the day on which patients initiated either SITA or SUs as add-ons to ongoing MET. This date occurred from 1 January 2009 through 31 December 2012 (index period). Baseline was defined as 12 months before the index date (not including the index date). Sulfonylureas included acetohexamide, chlorpropamide, glibenclamide, glimepiride, glipizide, glyburide, and tolazamide.
At baseline, only MET monotherapy was permitted (i.e. no SU, SITA, or any other antidiabetic medication was allowed). Eligible subjects had at least 45 days of MET coverage within 90 days before the index date (when SU or SITA was added). This requirement was included to ensure that initiation of SU or SITA was as an add-on therapy to MET as opposed to initial combination therapy.
The follow-up period was defined as the time from the index date until a therapeutic gap of ≥90 days with no SITA or SU prescription, the end of the study, the end of continuous enrollment, or a pregnancy/gestational diabetes event, whichever occurred earlier. The minimum follow-up period was 3 months for an index date of 31 December 2012, to a maximum of 51 months for an index date of 1 January 2009. Eligible patients were aged ≥18 years and had a diagnosis of T2DM based on the presence of disease-related codes (250.X0 or 250.X2; with X not being 1 [i.e. no code of 250.10 or 250.12 was permitted]) from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) during the baseline period. Also required was continuous coverage in the health plan for 12 months before and ≥90 days after the index date.
Patients were excluded if they had a diagnosis of type 1 diabetes (ICD-9-CM code 250.X1 or 250.X3), ketoacidosis (ICD-9-CM code 250.1), secondary diabetes (ICD-9-CM code 249.0), or gestational diabetes (ICD-9-CM code 648.8). Pregnancy at any time during the study and/or moderate-to-severe renal impairment (a relative contraindication to MET) during the 1-year baseline period were further exclusion criteria. (In the statistical analysis, data from patients who became pregnant and/or had gestational diabetes after the index date were censored.)
The proportion of days covered (PDC) was computed to determine medication adherence using the following formula: Adherence was assessed as both a continuous outcome (i.e. mean PDC) and a dichotomous measure (numbers [%] of patients with PDC ≥80 %). Medication persistence was defined as the proportion of patients who continued to use their index medications at 1, 2, and 3 years after the index date. Only adherence to MET + SU and MET + SITA (not to any other antidiabetic medications) was evaluated.
Discontinuation of SITA or SU was defined as any therapy gap ≥90 days during follow-up. Certain regimen changes were not considered as discontinuations of initial therapy, namely: (i) switches within the SU class; (ii) switches from SITA + MET to a fixed-dose combination (FDC) of SITA/MET (i.e. Janumet; Merck & Co., Inc., Kenilworth, NJ, USA); or (iii) switches from coadministration of SU + MET to FDCs of SU/MET (e.g. Glucovance; Bristol-Myers Squibb, New York, NY, USA). Continuous use of therapy was defined as gaps of <90 days between a dispense date plus days of supply and the subsequent dispense (refill) date.
Out of pocket expenses comprised the sum of copays, coinsurance, and deductibles. Average out-of-pocket expense was computed as the out-of-pocket expense divided by the days of supply of the index medication.
Descriptive analyses were conducted to examine baseline characteristics of SITA + MET and SU + MET users. We adjusted for potential imbalances in baseline characteristics (e.g. demographic variables, clinical measures, comorbidities) between these groups via propensity score (PS) matching. Comorbidities (based on available information in the administrative claims database analysis) included alcohol abuse, cancer, depression, hemiplegia, infections, and the following conditions: cardiovascular, cerebrovascular, dermatologic, gastrointestinal, hematologic, hepatic, metabolic, musculoskeletal, neurologic, ophthalmic, and urologic. The SU and SITA groups were also PS matched on concomitant medications, including antihypertensive drugs, beta-blockers, the endothelin receptor antagonist bosentan, the anti-arrhythmic agent disopyramide, lipid-lowering medications, loop diuretics, monoamine oxidase inhibitors, and non-steroidal anti-inflammatory drugs.
Members of the SITA + MET and SU + MET cohorts were matched in a 1: 1 ratio on duration of follow-up and PS. The PSs were computed with multivariate logistic regression models that included all variables contained within the database, including age, gender, baseline MET PDC, comorbidities, and concomitant medications.
The Kaplan-Meier method was used to estimate the distribution function for time to discontinuation in each cohort. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) of medication discontinuation. We began with Model 1 in the above-mentioned study sample (PS-Matched Sample 1), which is a naïve model with a single independent variable (SITA or SU). We then estimated Model 2 by adding out-of-pocket expense as a covariate to Model 1.
Linear regression analyses with generalized estimating equations (GEEs) were conducted to determine associations between SITA (vs SUs) + MET and mean PDC (continuous variable), whereas conditional logistic regression analyses were performed to determine associations between these regimens and the probability of achieving PDC ≥80 % (dichotomous variable). Student's t-tests were used to compare continuous variables and χ 2 tests were used for categorical variables. Data after PS matching are considered as correlated between paired patients. The GEE is a method of parameter estimation for correlated data. If such a correlation were not taken into account, standard errors of the parameter estimates would not be valid and hypothesis testing results would not be replicable. 34 Linear regression and logistic regression analyses were performed using the GENMOD procedure in SAS version 9.3 (SAS Institute, Cary, NC, USA) with repeated measures where matched pairs were considered. All statistical tests were conducted at a two-tailed α = 0.05. Relative risks were computed as HRs and adjusted odds ratios (ORs) with 95 % confidence intervals (CIs).
Results
In all, 34 113 patients added SUs and 14 947 added SITA to ongoing MET (Fig. 2) . Most of the 8202 patients who were excluded were diagnosed as having T1DM (n = 6606) and/or renal impairment (n = 988). Approximately 99 % (14 807/14 947) of SITA patients were PS matched.
The PS-matched cohorts (each group n = 14 807) used in Models 1 and 2 were well balanced (Table 1) . Standardized differences were <|0.1| for the key covariates of age, gender, diabetic microvascular and macrovascular complications, and the baseline PDC on MET monotherapy within the last 180 days before the index date. Most patients were men, resided in urban settings, and were covered by preferred-provider organizations.
The 1-year mean PDC was significantly higher in patients receiving SITA + MET compared with SU + MET within the matched cohorts (Model 1; Table 2) . At 1 year, 59.1 % of patients receiving SITA + MET were adherent (i.e. had PDC ≥80 %), compared with 55.9 % with SU + MET (P < 0.001; Fig. 3 ). Corresponding values (in favor of SITA + MET over SU + MET) were 52.6 % and 49.9 % (P = 0.007) at 2 years. The difference in adherence in favor of SITA (vs SU) + MET was not significant at 3 years (P = 0.447). Numbers of patients who continued to use SITA + MET at the end of 1, 2, and 3 years were significantly higher compared with SU + MET (Table 2; all P < 0.050).
Adherence to SITA + MET was significantly higher than to SU + MET across most categorical and continuous measures, in both models. Upon both linear regression with GEE on mean PDC, and logistic regression analysis on proportions of patients with PDC ≥ 80 %, adherence advantages in favor of SITA (vs SUs) were significant and of similar direction and magnitude (Tables 3, 4) .
The median time to discontinuation was 133 days longer in Model 1 with SITA (vs SU) + MET (Table 5 ). In each model, the likelihood of discontinuation during the observation period was significantly (P < 0.001) lower with SITA + MET compared with SU + MET: approximately 8 % less likely in Model 1 and 15 % less likely in Model 2. In Model 2, increasing out-of-pocket expense was associated with a significantly increased risk of discontinuation of the index medication (HR 1.116; 95 % CI 1.093-1.140; P < 0.001).
Discussion
To our knowledge, the present study is the first observational study to assess patient OAHA use to accomplish the following threefold aim: (i) to demonstrate, across Data are presented as the mean ± SD or as n (%). Some percentages do not sum to 100 because of rounding. CDHP, capital district physicians' health plan; EPO, exclusive provider organization; HDHP, high-deductible health plan; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization.
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three different measures, that patients were significantly more likely to continue using SITA (vs SU) + MET; (ii) to adjust for potential intergroup imbalances (and/or biases) via a PS-matching procedure; and (iii) to take into account out-of-pocket expense as an independent variable in statistical models (Model 2). Patients adding SITA (vs SU) to MET exhibited higher adherence (mean PDC and percentage of patients with PDC ≥80 %), greater persistence, and a longer median time to discontinuation.
In the present study, increasing out-of-pocket expense was associated with significantly reduced OAHA adherence in general, in line with health economics literature. However, the present study also showed increased adherence (on both logistic and linear regression analyses) and a reduced likelihood of regimen discontinuation (on survival analysis) for SITA + MET compared with SU + MET.
In Model 2, where out-of-pocket expenses were taken into account in estimating outcomes, incremental differences between SITA and SU on study outcomes were greater than those in Model 1, in which out-of-pocket expenses were not taken into account. It is likely that Model 1 underestimates incremental differences in adherence, persistence, and discontinuation between SITA and SU given that out-of-pocket expenses are set at higher levels for SITA versus SU by most insurance plans.
The fact that significantly higher proportions of the SITA (vs SU) + MET patients had PDC ≥80 % is potentially important because the OR of hospitalization for T2DM increased more than twofold in patients who received <80 % of their prescribed OAHA medications (OR 2.53; 95 % CI 1.38-4.64; P ≤ 0.01) in a US administrative-claims database analysis. 35 The results of the present study confirm and extend conclusions from recent observational studies comparing adherence between DPP-4 inhibitors and SUs (and/or other antidiabetic drugs), either alone or in combination with MET. 24, [36] [37] [38] For instance, the median treatment duration was nearly twofold higher with SITA (vs SU) + MET in a French primary care study 36 : 43.2 versus 20.2 months (P < 0.0001). A multivariate analysis with PS adjustment determined that patients using SITA (vs SU) + MET were 30 % less likely to change treatment (relative risk 0.70; 95 % CI 0.62-0.78; P < 0.0001). 36 Broadly similar findings resulted from a recent study that also interrogated the MarketScan Truven Health claims data base to evaluate adherence to SUs and DPP-4 inhibitors as monotherapy rather than as added to MET. 39 The retrospective cohort analysis by Farr et al. 39 included multivariate Cox proportional hazards 39 Conversely, initiators of SUs were significantly more likely to discontinue therapy (vs DPP-4 inhibitors) within the first year (adjusted HR 1.390; 95 % CI 1.363-1.418; P < 0.001). 39 Other studies were more similar to our own in analyzing adherence to MET along with DPP-4 inhibitors or SUs. In an Italian study that included PS matching, patients adding SITA to MET were 64 % more likely to be adherent compared with those adding SUs (OR for adherence with SUs vs SITA =0.36; 95 % CI 0.20-0.64; P < 0.001). 40 In that retrospective administrative-claims database analysis, patients who used SITA also experienced significantly lower unadjusted rates of all-cause hospitalization: 1.64/100 person-years (PY) versus 10.42/100 PY with SUs (incidence rate ratio = 0.21; 95 % CI 0.05-0.86; P = 0.030). 40 Similar findings were reported in a Spanish review of electronic medical records (EMRs) in primary care practices. 37 compared with patients receiving MET + any antidiabetic therapy (including insulin), individuals treated with DPP-4 inhibitors + MET exhibited significantly higher frequencies of adherence (70.3 % vs 59.6 %), persistence (63.4 % vs 51.0 %), and HbA1c <7 % (64.3 % vs 59.6 %; all P < 0.001). Recipients of DPP-4 inhibitors (vs other therapies) also had significantly lower frequencies of hypoglycemia (13.9 % vs 44.3 %), cardiovascular events (3.7 % vs 7.6 %), and total costs (€2347 vs €2682; all P < 0.05). 37 For many patients and their physicians, concerns about hypoglycemia and weight gain represent treatment barriers, potentially resulting in reduced adherence and/or a failure to intensify therapy despite suboptimal glucose control (i.e. treatment inertia 41 ), with decreased overall treatment effectiveness. It is plausible that patients in the present study were more adherent to and persistent with the SITA/MET regimen compared with the SUs/MET regimen because of a decreased likelihood of hypoglycemia or weight gain with the DPP-4 inhibitor, but only a patient survey could determine patients' reasons for adhering to or discontinuing different OAHA regimens.
The present observational study enabled large numbers of patients (29 614 and 11 416 patients in the two PS-matched populations) to be followed in a naturalistic, real-world setting, including both ambulatory care visits and hospitalizations. Not only was PS matching effective in balancing the two cohorts, but the present study also incorporated out-of-pocket expense as an independent variable in a statistical model. Consequently, the findings should be generalizable to typical clinical practices, particularly in the management of patients with relatively recent-onset T2DM who are initiating oral, second-line OAHA therapy along with ongoing MET, largely irrespective of out-of-pocket expense level.
We compared SITA, which is administered once daily, with SUs; some of the latter medications are administered more than once daily. However, the administrative claims database did not allow for comparing adherence between SITA and SUs based on medication dosages. Measuring adherence based on the number of prescriptions dispensed may result in an overestimate if patients did not actually take the medications or an underestimate if patients took less than the originally prescribed dose at the advice of their physicians (particularly for SUs, where downtitration is not uncommon). The retrospective cohort design of the present study and the administrative claims database that it analyzed were not compatible with the aim of explaining why patients discontinued SITA or SUs. In addition, the present study could not evaluate clinical complications resulting in differences in SITA and SU adherence profiles. Treatment adherence, including measures of proportions of patients with PDC ≥80 %, was statistically significantly higher in the SITA (vs SU) group at 1 and 2 years, but the difference narrowed and was not statistically significant at Year 3. This finding may reflect a more dynamic clinical situation at Year 3, with more frequent switching to (or adding) alternative regimens to keep pace with evolving β-cell dysfunction and overall clinical deterioration. In addition, observational studies cannot exclude biases and residual effects of unmeasured confounding variables and channeling bias, 24, 40 although our use of PS matching likely minimized intergroup imbalances due to non-randomized allocation.
Other frequent limitations of administrative claims databases are constraints on patient-level data, including sociodemographic and clinical factors. The present study did not provide information on a range of factors that can affect OAHA adherence, including socioeconomic status, health beliefs, levels of self-care (e.g. glucose monitoring), different coping strategies, 42 self-efficacy, 43 family support, 44, 45 and geographic region (urban versus rural residence, race, and ethnicity). 46 We assessed only OAHA adherence, not adherence to lifestyle counseling, injected therapies (e.g. insulin), or to other medications for comorbidities, such as dyslipidemia, hypertension, and depression. Studies indicate that a T2DM patient can expect to take five medications daily for all conditions (mean 8.9 in one study of elderly home-care patients 47 ), 48 and both polypharmacy and increased dosing frequency have been associated with reduced medication adherence. [49] [50] [51] Conversely, some studies of T2DM have reported higher medication adherence in patients who received more than four (vs four or fewer) antidiabetic medications 52 and/or had greater comorbidity burdens (a pattern potentially consistent with the Health Belief Model 53 ). 54 We did not compare adherence levels between patients taking regimens with different frequencies, distinct SU medications, or FDCs of SITA + MET or SU + MET regimens. A number of studies have pointed towards higher adherence to FDCs (vs loose-pill combinations) of OAHAs. 55, 56 An EMR database analysis would be necessary to determine the consequences of different levels of adherence to SITA + MET (vs SU + MET) on metabolic control (e.g. laboratory data on HbA1c), the overall severity of diabetes, and/or the frequency or severity of vascular comorbidities or risk factors. We also could not assess frequencies or severities of untoward drug effects or drug-drug interactions, which can adversely affect treatment adherence and other health outcomes. 47 The present study's requirement of continuous health plan enrollment may have led us to overestimate adherence, which is positively associated with continuity of care. 57 Despite this potential overestimation, it is of some concern that less than half the patients in both cohorts had PDC ≥80 % at 3 years. However, adherence to therapy is known to be poor in a chronic disease such as diabetes. 51 Another limitation to the present study is the lack of information on glycemic control and what happened after stopping the medications studied. It is possible that SU was started by some clinicians because their patients had more symptoms of diabetes or a higher HbA1c compared with those prescribed SITA. Such patients may have had more severe β-cell dysfunction and progression of diabetes, leading to faster treatment failure and hence necessitating the addition of another medication, including insulin. An EMR or other study would be necessary to determine which new regimens were instituted in patients who discontinued SITA (or SU) + MET. Other potential limitations of the present study include the facts that prescription claims do not equate to medications taken and that ICD-9-CM codes were developed for reimbursement, not specifically case ascertainment, purposes.
Renal impairment is a common complication of diabetes, and many SUs are not recommended for use in this population. Patients with moderate-to-severe renal impairment were excluded in order to limit the confounding effect of this factor on treatment adherence and persistence. Severe hepatic dysfunction is not common, and it was not considered necessary to exclude patients on this basis. In addition, liver dysfunction was one of the variables in the PSM protocol potentially limiting intergroup differences.
In conclusion, adults with T2DM who initiated SITA (vs SUs) as add-ons to ongoing MET had improved medication adherence, greater persistence, and prolonged times to discontinuation in naturalistic clinical settings. To our knowledge, this is the first "realworld" observational study to demonstrate improved outcomes with the DPP-4 inhibitor SITA over SUs across all three of these measures while also adjusting for potential intergroup imbalances via a PS-matching procedure and statistical models that included out-ofpocket expense as an independent variable. The finding of higher SITA (vs SU) + MET adherence at treatment Years 1 and 2 was robust, with a consistent direction and magnitude of results in all statistical models. Further research is needed to evaluate the potential clinical and Adherence to sitagliptin vs. sulfonylureas Z.T. BLOOMGARDEN et al.
economic consequences of these findings and to determine physicians' and patients' reasons for discontinuing medications.
